Author of

• 18749

  +

  P3.07 - Poster Session with Presenters Present (ID 493)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Regional Aspects/Health Policy/Public Health
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 18770

    +

    P3.07-021 - Prevalence of EGFR Mutations in Brazilian Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (ID 5840)

    14:30 - 14:30  |  Author(s): G.P.R. Martins
    • Abstract
    • Slides

    Background:
    Non-small cell lung cancer (NSCLC) accounts for approximately 85% of primary lung cancers, the majority of patients presenting with advanced disease at diagnosis. In the last decades there has been significant progress in the understanding of lung cancer molecular biology, which has influenced on treatment choices. The prevalence of EGFR mutations in non-squamous NSCLC population range from 15% to 40%, depending on the population that has been assessed. Brazilian people are marked by high miscegenation, and there is lack of data about EGFR mutations in this population. This study intends to report the prevalence of such mutations in Brazil.
    
    Methods:
    We performed an observational retrospective study of 324 patients treated for advanced NSCLC from january 2014 to may 2016 from two institutions. 80 (24,7%) patients had squamous NSCLC and were not tested for EGFR mutations. The others 244 non-squamous NSCLC patients had their medical record reviewed and information regards the EGFR mutation status were obtained. Patients were stratified by sex, age, histological subtype, and type of mutation.
    
    Results:
    51 cases (22% of adenocarcinomas) with EGFR mutations were identified. The most frequent genetic alteration detected was exon 19 deletion (64,7%), followed by L858R mutation (19,6%). 34 EGFR mutated patients (66,7%) were women, as man accounted for 60% of all the NSCLC cases.
    
    Conclusion:
    Our findings support previous studies that showed an EGFR mutation rate about 20% in non-squamous NSCLC and its higher prevalence in women population. This research is also important in terms of public health, since knowing how many cases of mutated NSCLC are expected in this region, better we can manage the costs of these patients treatments.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.